Table 6. Polypharmacology of currently approved anticancer drugs.
Drug | Indication | Drug Bank Targets | PubChem Off-Target |
---|---|---|---|
Sunitinib | renal cell carcinoma | 8 | ~150 |
Sorafenib | advanced renal cell carcinoma, liver cancer | 7 | ~120 |
Tamoxifen | breast cancer | 2 | ~70 |
Paclitaxel | lung, ovarian, and breast cancer | 2 | 4 |